#sicklecellgenetherapy
LightNews LightNews
hemehub.bsky.social
Our session with Dr. Thomas Coates is in 2 weeks!

Don’t miss this opportunity to hear from a top expert in the field!

🔗Register now:
hemehub.org/live-events

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine
hemehub.bsky.social hemehub.bsky.social @hemehub.bsky.social · Oct 18
🩸Join us for an exclusive webinar with Dr. Thomas Coates, focusing on advances in the management of sickle cell disease, vascular complications, and transfusion-related iron overload.

Register now: hemehub.org/live-events

#Hematology #SickleCellDisease #BloodDisorders #MedicalEducation
October 22, 2025 at 10:58 PM
4040rec.bsky.social
#haematology #Sicklecelldisease #sicklecellgenetherapy #genetherapy #geneeditingtherapy #Casgevy #Exacel @vertexpharma.bsky.social #NHS #haemoglobin #clinicaltrials #functionalcure @AmandaPritchard #geneeditingtool #Crispr #editedstemcells #NHSEngland #clinicaltrials
www.bbc.co.uk/news/article...
NHS to offer 'groundbreaking' sickle cell gene therapy
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.
www.bbc.co.uk
February 3, 2025 at 1:36 PM
hemehub.bsky.social
Additional facts about the Exa-cel (Exagamglogene Autotemcel, Casgevy) Study

Focus: CLIMB SCD-121 Trial

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
October 22, 2025 at 4:00 AM
hemehub.bsky.social
Further results from the Exa-cel study.

Focus: CLIMB SCD-121 Trial

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy #HematopoieticStemCells
October 22, 2025 at 10:58 PM
hemehub.bsky.social
Facts about the Exa-cel (Exagamglogene Autotemcel, Casgevy) Study

Focus: CLIMB SCD-121 Trial

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy
October 20, 2025 at 6:15 PM
hemehub.bsky.social
🩸 Today’s question addresses long-term safety considerations for patients treated with Lyfgenia, focusing on which risks require ongoing surveillance.

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials
October 22, 2025 at 4:01 AM
hemehub.bsky.social
Missed our session with Dr. Thomas Coates on Sickle Cell Disease and Gene Therapy?

The full recording is now available on our YouTube channel!

➡️Watch the full session: youtu.be/TDNCgKR3p18?...

#GeneTherapy #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #RareDiseases
December 1, 2025 at 2:19 AM
hemehub.bsky.social
🧬The second question of the day focuses on how patient-reported outcomes reflect clinical benefit after Casgevy therapy.

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
October 29, 2025 at 7:03 PM
hemehub.bsky.social
Additional results from the Exa-cel study.

Focus: CLIMB SCD-121 Trial

#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy @ash.hematology.org @asgct.bsky.social @genesndiseases.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org
October 26, 2025 at 12:42 AM